Myeloperoxidase and High-Sensitivity C-Reactive Protein for Predicting Major Adverse Cardiovascular Events in Patients with Coronary Heart Disease

Background: Research has shown that high-sensitivity C-reactive protein (hs-CRP) is a major inflammatory marker for prediction of acute coronary syndrome (ACS). Myeloperoxidase (MPO) also plays an important role in atherosclerosis initiation and development. In present study, the major adverse cardiovascular events (MACEs) of patients with coronary heart disease (CHD) were investigated. Methods: MPO, hs-CRP and ACS-related risk factors from 201 ACS (78 AMI and 123 UAP) and 210 non-ACS (84 SAP and 126 non-CHD) patients confirmed by coronary angiography were detected, and the data were analyzed with receiver operating characteristic (ROC) curve and Spearman’s correlation coefficients. MACEs of 285 CHD patients were investigated during the 4-year period follow-up from March 2010 to May 2014. Results: The areas under ROC curve for diagnosing ACS were 0.888 (95% CI 0.843 - 0.933) for MPO, and 0.862 (95% CI 0.815-0.910) for hs-CRP, respectively. There were significantly correlations between MPO and hs-CRP in both ACS and non-ACS groups. Regarding to ACS patients, both MPO and hs-CRP were positively correlated with BMI, TC, TG, LDL-C and Hcy. Prospective study demonstrated that the incidences of MACEs associated significantly with elevated MPO baseline level (yes vs no, OR 7.383, 95% CI 4.095 - 13.309) and high hs-CRP baseline level (yes vs no, OR 4.186, 95% CI 2.469 - 7.097) in CHD patients. Conclusions: The present study provides the epidemiological evidence that elevated baseline MPO and hs-CRP levels are both valuable predictors of MACEs in CHD patients. MPO and hs-CRP would prompt the progression of atherosclerosis and development from SAP to ACS.

Effects of adjuvant Chinese patent medicine therapy on major adverse cardiovascular events in patients with coronary heart disease angina pectoris:a population-based retrospective cohort study

Objective: This study aimed to explore the effects of Chinese patent medicine(CPM) in reducing the incidence of major adverse cardiovascular events(MACE) in patients with coronary heart disease(CHD) angina pectoris and improving clinical effectiveness and provide evidence for its use as clinical adjuvant therapy.Methods: Twenty-eight thousand five hundred and seventeen patients hospitalized with CHD angina pectoris from 6 hospitals were divided into CPM group(n = 11,374) and non-CPM group(n = 17,143) to evaluate the incidence of MACE, including myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting.Results: The incidence of MACE in the CPM group was lower than that in the non-CPM group. CPM therapy was an independent protective factor that reduced the overall risk of MACE [adjusted hazard ratio = 0.40, 95% confidence interval(0.33;0.49)]. Patients in the CPM group who received one, two, or three types of CPM could benefit from adjuvant treatment with CPM, and taking more types of CPM was associated with a lower risk of MACE. In addition, the male population was better than the female population at taking CPM, and middle-aged people aged 55 to 64 were more suited to take CPM based on Western medicine.Conclusions: The use of CPM as adjuvant therapy can decrease the occurrence of MACE in patients with CHD angina pectoris,especially in men and middle-aged people, and the drug treatment plan should be optimized accordingly. However, this conclusion needs further verification by prospective cohort studies in the future.

Clinical perspective on C-reactive protein in prognostication of major adverse cardiac events in the elderly with established coronary heart disease

The systemic response to tissue injury, regardless of cause is characterized by a cytokine-mediated alteration in the hepatic synthesis of a number of different plasma proteins,known collectively as 'acute phase reactants'. These proteins include C-reactive protein, serum amyloid A protein, alphal glycoprotein, ceruloplasmin, alpha macroglobulins, complement components (C1-C4, factor B, C9, C11), alpha1antitrypsin, alpha1 antichymotrypsin, fibrinogen, prothrombin,factor Ⅷ, plasminogen, haptoglobin, ferritin, immunoglobulins and lipoproteins. The initiation of the acute phase response is linked to the production of hormone-like polypeptide mediators now called cytokines, namedly, interleukin 1(IL-1),tumor necrosis factor, interferon gamma, interleukin 6 (IL-6),leukemia inhibitory factor, ciliary neurotropic factor, oncostatin M, and interleukin 11 (IL- 11).……

Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease:A review of the literature

Tumor necrosis factor inhibitors(anti-TNFs)are widely used therapies for the treatment of inflammatory bowel diseases(IBD);however,their administration is not risk-free.Heart failure(HF),although rare,is a potential adverse event related to administration of these medications.However,the exact mechanism of development of HF remains obscure.TNFαis found in both healthy and damaged hearts.Its effects are concentration-and receptor-dependent,promoting either cardio-protection or cardiomyocyte apoptosis.Experimental rat models with TNFαreceptor knockout showed increased survival rates,less reactive oxygen species formation,and improved diastolic left ventricle pressure.However,clinical trials employing anti-TNF therapy to treat HF had disappointing results,suggesting abolishment of the cardioprotective properties of TNFα,making cardiomyocytes susceptible to apoptosis and oxidation.Thus,patients with IBD who have risk factors should be screened for HF before initiating anti-TNF therapy.This review aims to discuss adverse events associated with the administration of anti-TNF therapy,with a focus on HF,and propose some approaches to avoid cardiac adverse events in patients with IBD.

Etomidate vs propofol in coronary heart disease patients undergoing major noncardiac surgery:A randomized clinical trial

BACKGROUND The ideal depth of general anesthesia should achieve the required levels of hypnosis,analgesia,and muscle relaxation while minimizing physiologic responses to awareness.The choice of anesthetic strategy in patients with coronary heart disease(CHD)undergoing major noncardiac surgery is becoming an increasingly important issue as the population ages.This is because general anesthesia is associated with a risk of perioperative cardiac complications and death,and this risk is much higher in people with CHD.AIM To compare hemodynamic function and cardiovascular event rate between etomidate-and propofol-based anesthesia in patients with CHD.METHODS This prospective study enrolled consecutive patients(American Society of Anesthesiologists grade II/III)with stable CHD(New York Heart Association class I/II)undergoing major noncardiac surgery.The patients were randomly allocated to receive either etomidate/remifentanil-based or propofol/remifentanil-based general anesthesia.Randomization was performed using a computer-generated random number table and sequentially numbered,opaque,sealed envelopes.Concealment was maintained until the patient had arrived in the operating theater,at which point the consulting anesthetist opened the envelope.All patients,data collectors,and data analyzers were blinded to the type of anesthesia used.The primary endpoints were the occurrence of cardiovascular events(bradycardia,tachycardia,hypotension,ST-T segment changes,and ventricular premature beats)during anesthesia and cardiac troponin I level at 24 h.The secondary endpoints were hemodynamic parameters,bispectral index,and use of vasopressors during anesthesia.RESULTS The final analysis included 40 patients in each of the propofol and etomidate groups.The incidences of bradycardia,hypotension,ST-T segment changes,and ventricular premature beats during anesthesia were significantly higher in the propofol group than in the etomidate group(P<0.05 for all).The incidence of tachycardia was similar between the two groups.Cardiac troponin I levels were comparable between the two groups both before the induction of anesthesia and at 24 h after surgery.When compared with the etomidate group,the propofol group had significantly lower heart rates at 3 min after the anesthetic was injected(T1)and immediately after tracheal intubation(T2),lower systolic blood pressure at T1,and lower diastolic blood pressure and mean arterial pressure at T1,T2,3 min after tracheal intubation,and 5 min after tracheal intubation(P<0.05 for all).Vasopressor use was significantly more in the propofol group than in the etomidate group during the induction and maintenance periods(P<0.001).CONCLUSION In patients with CHD undergoing noncardiac major surgery,etomidate-based anesthesia is associated with fewer cardiovascular events and smaller hemodynamic changes than propofol-based anesthesia.

The Outcomes of Pregnancy with Congenital Heart Disease: An Integrative Literature Review

Purpose: The purpose of this review was to identify the short-term and long-term outcomes of pregnancy in women suffering from congenital heart disease (CHD). Methods: An integrative review is used to identify the pregnancy outcomes in women with CHD. Data search was between 2010 and 2020 using Google Scholar, Scopus, Web of Science, Science Direct, Pub Med, Medline, CINAHL, EBSCO, Cochrane, and EBSCO host. Sixteen articles met the eligibility criteria. Results: The sixteen reviewed articles utilized descriptive retrospective and prospective design. Themes were short-term outcomes that include;cardiac maternal and obstetric outcomes, and long-term outcomes. Conclusion: Previous uncertainty about the ability of CHD patients to successfully become pregnant and deliver safely has replaced by the recognition that a large number can have excellent outcomes. However, these patients do continue to have higher cardiac, obstetric, and fetal risks than the general population. This illuminates the importance of preconception counseling and risk assessment for women suffering from CHD regarding the expected maternal and fetal outcomes. Moreover, there is a need for providing accurate and appropriate education about pregnancy and delivery options.

Association of fatigue with short-term prognosis in young and middle-aged patients with coronary heart disease

Background:To investigate the effect of fatigue on the short-term prognosis of young and middle-aged patients with coronary heart disease(CHD).Methods:A cross-sectional,observational survey was distributed at a tertiary hospital in Suzhou,China.Patients were assessed for fatigue and their prognosis was assessed at 3 and 6 months after discharge.General Information Questionnaire,Fatigue Scale and Seattle Angina Questionnaire(SAQ)were used for the survey.The Cox proportional hazard model was used to analyze the impact of fatigue on the occurrence of major adverse cardiac events(MACEs)at 3 and 6 months after discharge.Multiple linear regression models were used to analyze the effect of fatigue on health-related quality of life(HRQoL)at 3 and 6 months after discharge.Results:199 patients were followed up with in the end.43 patients(21.6%)with MACE three months after discharge had a total SAQ score of(399.76±39.61).The overall SAQ score was(425.14±22.66)and 52 patients(26.1%)experienced MACE six months after discharge.Fatigue was identified as a risk factor for MACE 6 months after discharge by the Cox proportional hazard model(HR=2.939,95%CI:0.177~0.655,P=0.001)and as an independent risk factor for quality of life 3 and 6 months after discharge by multiple linear regression(P<0.001).Conclusions:In individuals who are young or middle-aged and have coronary heart disease,fatigue is a risk factor for the short-term prognosis.It is advised that clinical professionals prioritize patient fatigue assessment and improve management of fatigue symptoms.

Comparison of clinical outcomes of Chinese men and women after coronary stenting for coronary artery disease:a multi-center retrospective analysis of 4,334 patients

The outcome differences between Chinese male and female patients within one-year follow-up after percutaneous coronary intervention（PCI） with stent remain unclear.The present study was aimed to compare clinical outcomes in such two populations.From May 1999 to December 2009,4,334 patients with acute myocardial infarction（MI）,unstable angina,stable angina,or silent ischemia,who underwent PCI,were registered at our centers.Among these,3,089 were men and 1,245 were women.We compared these groups with respect to the primary outcomes of MI and secondary outcomes including a composite of major adverse cardiac events（MACE） including cardiac death,MI,target lesion revascularization,target vessel revascularization（TVR）,stent thrombosis（ST）,definite ST and probable ST at one-year follow-up.Chinese male patients had a higher MACE rate（13%vs.10.7%,P =0.039）,mainly led by TVR（9.09%vs.6.98%,P=0.024） at one year,which was significantly different than female patients.Chinese male and female patients showed a significant difference on MACEs.However,there was no significant difference with respect to MI between these groups.

Multifactor Dimensionality Reduction Analysis of the Correlation of Chinese Medicine Syndrome Evolvement and Cardiovascular Events in Patients with Stable Coronary Heart Disease

Objective： To analyze the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease （CHD）. Methods： This prospective cohort study investigated and collected the clinical information of patients with stable CHD and observed the syndrome type at the baseline and 6-month at follow-up, as well as the cardiovascular events during the 6-month and 12-month follow-up. The patients were divided into the event group and the non-event group. The interaction and the impact of syndrome evolvement on cardiovascular events were examined through multifactor dimensionality reduction （MDR） analysis and the results were verified by Chi-square test. Results： Totally 1,333 of 1,503 stable CHD patients enrolled met the inclusion criteria of MDR analysis. Among them, 959 （71.9%） cases were males and 374 （28.1%） cases were females. Thirty seven cases had cardiovascular events during 6 to 12 months after the study began. The results of the MDR analysis and verification using Chi-square test showed that the development of cardiovascular events was positively correlated with interaction between blood stasis and toxic syndrome at the baseline, blood stasis at the baseline and qi deficiency at the 6-month follow-up, toxic syndrome at the baseline and qi deficiency at the 6-month follow-up, toxic syndrome at the base line and blood stasis at the 6-month follow-up, qi deficiency and blood stasis at the 6-month follow-up （P〈0.05 for all）. Conclusions： Blood stasis, toxic syndrome and qi deficiency are important factors of stable CHD. There are positive correlation between cardiovascular events and syndrome evolution from blood stasis to qi deficiency, from toxic syndrome to qi deficiency and from toxic syndrome to blood stasis, indicating the pathogenesis of toxin consuming qi, toxin leading to blood-stasis in stable CHD patients prone to recurrent cardiovascular events.

Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease

Objective: To examine the prognostic value of serum levels of asymmetric dimethylarginine(ADMA)in patients with stable coronary heart disease(CHD) thus explore a potential biomarker of "toxin syndrome" in CHD.Methods: In this prospective nested case-control study, 36 of 1,503 Chinese patients with stable CHD experienced at least 1 recurrent cardiovascular event(RCE) during 1-year fol ow-up. Serum levels of ADMA at the start of fol ow-up were compared between these 36 cases and 36 controls which matched to cases in terms of gender, age, history of hypertension, and myocardial infarction. Results: Based on the crude model, subjects in the 2 highest ADMA quartiles showed signi?cantly higher risk of developing RCE than those in the lowest ADMA quartile [odds ratio(OR) 4.09, 95%confidence interval(CI) 1.01 to 16.58; OR 6.76, 95% CI 1.57 to 29.07]. This association was also observed in the case-mix model(OR 5.51, 95% CI 1.23 to 24.61; OR 7.83, 95% CI 1.68 to 36.41) and multivariable model(OR 6.64,95% CI 1.40 to 31.49; OR 13.14, 95% CI 2.28 to 75.71) after adjusting for confounders. The multivariable model which combined ADMA and high-sensitivity C-reactive protein(hs CRP) showed better predictive power with areas under the receiver operator characteristic curves(0.779) than the model of either ADMA(0.694) or hs CRP(0.636). Conclusion:Serum ADMA level may be a potential biomarker of "toxin syndrome" in CHD which shows favorable prognostic value in predicting 1-year RCE in patients with stable CHD. [The registration number is Chi CTR-PRNRC-07000012]

Risk factors for perioperative major cardiac events in Chinese elderly patients with coronary heart disease undergoing noncardiac surgery

Background Few studies have investigated perioperative major adverse cardiac events （MACEs） in elderly Chinese patients with coronary heart disease （CHD） undergoing noncardiac surgery. This study examined the incidence and risk factors for perioperative MACE in elderly patients who underwent noncardiac surgery, and established a risk stratification system. Methods This retrospective observational clinical study included 482 patients aged -〉60 years with CHD who underwent elective major noncardiac surgery at the Peking Union Medical College Hospital. The primary outcome was MACE within 30 days after surgery. Risk factors were evaluated using multivariate Logistic regression analysis. Results Perioperative MACE occurred in 61（12.66%） of the study patients. Five independent risk factors for perioperative MACE were identified： history of heart failure, preoperative arrhythmia, preoperative diastolic blood pressure 〈75 mmHg, American Society of Anesthesiologists grade 3 or higher, and intraoperative blood transfusion. The area under the receiver operating characteristic curve for the risk-index score was 0.710＋0.037. Analysis of the risk stratification system showed that the incidence of perioperative MACE increased significantly with increasing levels of risk. Conclusions Elderly Chinese patients with CHD who undergo noncardiac surgery have a high risk of perioperative MACE. Five independent risk factors for perioperative MACE were identified. Our risk stratification system may be useful for assessing perioperative cardiac risk in elderly patients undergoing noncardiac surgery.

Thinking on Treatment of Post-reperfusion Events in Patients with Coronary Heart Disease by Integrated Traditional Chinese and Western Medicine

In the 1970＇s, promoting blood circulation to remove blood stasis （PCRS） was the main method in integrative traditional Chinese and Western medicine （ICWM） in treating acute myocardial infarction （AMI）. It decreased the case fatality rate of AMI from 30% to 13%-16% as compared with that treated by simple Western internal medical conservative treatment. Later in the 1980＇s, such therapeutic approaches as infarction related arterial revascularization, thrombolysis and percutaneous coronary intervention （PCI） became the most effective means in treating AMI, which could re-canalize the obstructed coronary vessels, recover the blood perfusion of myocardium, and thus to save the ischemic myocardium, diminute the infarcted size, preserve the ventricular function and improve the patient＇s near and long-term prognosis, with the fatality rate reduced by 5%-7%. Hence, the some-time superiority of ICWM in treating AMI was overshadowed with no more luster left.

Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications

Lack of conclusive beneficial effects of strict glycemic control on macrovascular complications has been very frustrating for clinicians involved in care of patients with diabetes mellitus (DM). Highly publicized controversy surrounding cardiovascular (CV) safety of rosiglitazone resulted in major changes in United States Food and Drug Administration policy in 2008 regarding approval process of new antidiabetic medications, which has resulted in revolutionary data from several large CV outcome trials over the last few years. All drugs in glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitor classes have shown to be CV safe with heterogeneous results on CV efficacy. Given twofold higher CV disease mortality in patients with DM than without DM, GLP-1 RAs and SGLT-2-inhibitors are important additions to clinician’s armamentarium and should be second line-therapy particularly in patients with T2DM and established atherosclerotic CV disease or high risks for CV disease. Abundance of data and heterogeneity in CV outcome trials results can make it difficult for clinicians, particularly primary care physicians, to stay updated with all the recent evidence. The scope of this comprehensive review will focus on all major CV outcome studies evaluating CV safety and efficacy of GLP-1 RAs and SGLT-2 inhibitors.

老年冠心病病人应用基于CGA的专科干预与反馈式健康宣教的效果观察

目的:探讨基于老年综合评估(CGA)的专科干预结合反馈式健康宣教在老年冠心病病人中的应用效果。方法:选取2020年10月—2022年10月本院收治的100例老年冠心病病人,采用随机数字表法分为甲组和乙组,各50例。甲组采用常规老年护理及健康教育,乙组予以基于CGA的专科干预联合反馈式健康宣教。观察两组应对方式、健康教育需求、自我管理能力及心脏不良事件发生情况。结果:与干预前相比,两组随访6个月的医学应对方式问卷(MCMQ)面对维度评分均升高,回避、屈服维度评分均降低,且乙组面对维度评分高于甲组,回避、屈服维度评分低于甲组,差异有统计学意义(P<0.05);两组随访6个月的心脏康复信息需求表(INCR)评分均低于干预前,冠心病自我管理量表(CSMS)评分均高于干预前,且乙组INCR评分较甲组低,CSMS评分较甲组高,差异有统计学意义(P<0.05);乙组随访6个月内心脏不良事件发生率低于甲组,差异有统计学意义(P<0.05)。结论:CGA下专科干预联合反馈式健康宣教能够改善老年冠心病病人对应对方式,满足其心脏康复健康教育需求,有助于提高病人自我管理能力,改善心脏不良事件控制效果。

冠状动脉CT血管造影预测冠心病患者发生左心室重构及远期心血管不良事件的价值

目的分析冠状动脉CT血管造影预测冠心病患者发生左心室重构及远期心血管不良事件的价值。方法选取郑州大学第一附属医院2021年1月至2022年7月诊治的120例冠心病患者,随访1 a,根据左心室重构发生情况分为左心室重构组(26例)、无左心室重构组(94例),根据心血管不良事件发生情况分为发生组(24例)、未发生组(96例)。比较不同组别患者冠状动脉CT血管造影结果,分析冠状动脉CT血管造影预测冠心病患者发生左心室重构及远期心血管不良事件的价值。结果左心室重构组、无左心室重构组在冠状动脉管腔狭窄程度和高危斑块特征方面的差异有统计学意义(P<0.05)。发生组、未发生组斑块总体积、钙化斑块体积、非钙化斑块体积、病变长度、斑块负荷比较,差异有统计学意义(P<0.05)。受试者工作特征(ROC)曲线分析显示,冠状动脉CT血管造影在预测冠心病患者发生左心室重构及远期心血管不良事件中具有较高的价值。结论冠状动脉CT血管造影在预测冠心病患者发生左心室重构及远期心血管不良事件中具有较高的价值。

基于血小板聚集率检测的阿司匹林剂量调整方案在儿童先心病抗栓治疗中是否更优

目的 以高危血栓风险先心病儿童为对象,针对阿司匹林治疗反应多样性及近远期血栓发生率仍较高的问题,评价基于血小板功能检测目标导向的阿司匹林个体化抗栓治疗方案的临床效果是否优于传统固定剂量的给药方案。方法 采用前瞻随机对照注册研究(ChiCTR2000036446)。纳入阜外医院小儿外科中心自2020年4月~2021年4月所有行先心病手术并且需要术后常规应用阿司匹林抗栓治疗的6岁内患儿。所有入组患儿随机分为阿司匹林固定剂量组3 mg/(kg·d)和剂量调控组。剂量调控组在3剂和6剂阿司匹林后分别行花生四烯酸诱导的血小板聚集率(PAG-AA)检测。对3剂后PAG-AA>20%者,阿司匹林加量至6 mg/(kg·d);6剂后PAG-AA仍>20%者,联用氯吡格雷0.2 mg/(kg·d)治疗。比较两组患者术后3月包括死亡在内的累计血栓事件发生率和出血事件发生率。结果 对比阿司匹林反应低下、血栓事件与出血不良事件,两组患者数据比较无统计学差异。在接受相同剂量的阿司匹林[3 mg/(kg·d),1次/d]连续3剂后,不同个体的PAG-AA存在较大差异。剂量调控组通过增加阿司匹林剂量,延长阿司匹林使用时间与联合用药,整体阿司匹林反应性得到了改善,但与固定剂量组比较无统计学差异。两组在术后3月接受随访期间以及最终复查时均无死亡病例发生,两组阿司匹林反应低下病例的血栓事件和出血事件发生率比较无明显差别。Spearman相关性检测显示阿司匹林低反应与血栓事件无明显的相关性。结论 与固定剂量阿司匹林抗栓治疗方案相比,基于血小板聚集率检测的阿司匹林剂量个体化抗栓治疗方案并不具有优越性,并不能显著降低先天性心脏病高危血栓风险患儿术后早期3月内血栓及出血事件发生率。血栓事件与阿司匹林反应低下无明显相关性。

肺源性心脏病患者24h动态心电图参数与肺功能的相关性及对不良事件的预测价值

目的探究肺源性心脏病(PHD)患者动态心电图参数与肺功能的相关性及对不良事件的预测价值。方法选取PHD患者73例为观察组,并纳入同期健康志愿者42例为对照组,两组均接受24 h动态心电图和肺功能检测;比较入组时两组被检者及观察组患者治疗前、治疗后第7天时24 h动态心电图参数[24 h RR间期标准差(SDNN)、每5 min时段正常RR间期标准差(SDANN)]和肺功能指标[1秒用力呼气容积(FEV1)/用力肺活量(FVC)、FEV1预计百分比(FEVl%)];随访6个月,根据不良事件发生情况将观察组分为预后良好组和预后不良组,比较两组患者临床特征,分析24 h动态心电图参数与肺功能的相关性及其对PHD不良事件的预测价值。结果观察组入院后SDNN、SDANN、FEV1/FVC、FEVl%低于对照组(P<0.05),73例PHD患者在治疗后第7天时的SDNN、SDANN、FEV1/FVC、FEVl%较治疗前升高(P<0.05);随访6个月,73例PHD患者中有32例出现不良事件,预后不良组急性加重期占比、平均病程均高于预后良好组(P<0.05),预后不良组治疗前、治疗后第7天时SDNN、SDANN、FEV1/FVC、FEVl%均低于预后良好组(P<0.05);Pearson相关分析结果显示,治疗前及治疗后第7天时SDNN、SDANN均与治疗前及治疗后第7天时FEV1/FVC、FEVl%呈正相关(P<0.05);ROC分析结果显示,PHD患者发生不良事件的治疗前、治疗后第7天时SDNN、SDANN的cut-off值分别为72 ms、55 ms、92 ms、91ms,AUC范围在0.702~0.813(P<0.05)。结论PHD患者治疗前及治疗后7 d的SDNN、SDANN与肺功能呈正相关,24 h动态心电图参数对PHD不良事件的具有一定的预测价值。

多维度协同护理在老年冠心病患者中的应用效果

目的:观察多维度协同护理在老年冠心病患者中的应用效果。方法:选取2020年3月至2022年6月该院收治的86例老年冠心病患者进行前瞻性研究,按照随机数字表法将其分为观察组与对照组各43例。对照组采用常规护理,观察组采用多维度协同护理,比较两组6 min步行试验距离(6MWD)、健康调查简表(SF-36)评分和心脏不良事件发生率。结果:护理后,两组6MWD长于护理前,且观察组长于对照组,差异均有统计学意义(P<0.05);护理后,两组SF-36各维度评分高于护理前,且观察组高于对照组,差异均有统计学意义(P<0.05);观察组心脏不良事件发生率为4.65%,明显低于对照组的20.93%,差异有统计学意义(P<0.05)。结论:多维度协同护理用于老年冠心病患者可延长其6MWD,提高其SF-36评分,降低其心脏不良事件发生率,效果优于常规护理。

心血管磁共振心肌灌注成像联合CT血流储备分数预测阻塞性冠心病发生心血管不良事件的价值

目的 探讨心血管磁共振(CMR)心肌灌注成像联合CT血流储备分数(CT-FFR)参数对阻塞性冠心病患者心血管不良事件发生的预测价值。方法 选取2018年6月—2022年6月在河北北方学院附属第二医院治疗的180例阻塞性冠心病(冠状动脉狭窄程度≥50%)患者进行前瞻性研究。所有患者行CT血管成像及CMR心肌灌注成像检查,并通过现场随访或电话随访等方式,收集患者1年内的心血管不良事件发生情况。采用单因素及多因素logistic回归模型分析发生心血管不良事件的影响因素;ROC曲线评估不同的预测模型对心血管不良事件发生的预测效能。结果 发生心血管不良事件的患者共45例为观察组,其余135例为对照组。与对照组比较,观察组年龄、男性占比、吸烟者占比、总胆固醇水平、合并糖尿病者占比、合并高脂血症者占比、首过灌注时间及心肌延迟强化信号值等指标升高,CT-FFR及最大上升斜率(Slopemax)指标则降低,差异均有统计学意义(P<0.05)。将以上指标进一步做单因素及多因素logistic回归分析,得出年龄、男性、吸烟、合并糖尿病、合并高脂血症及首过灌注时间、心肌延迟强化信号值是阻塞性冠心病患者发生心血管不良事件的独立危险因素(P<0.05),CT-FFR及Slopemax是其保护因素(P<0.05)。仅使用临床参数(包括年龄、性别、吸烟、糖尿病、高脂血症等疾病)时的ROC曲线下面积为0.721(95%CI:0.645~0.812);CMR心肌灌注成像联合CT-FFR的ROC曲线下面积为0.793(95%CI:0.713~0.873);在CMR心肌灌注成像联合CT-FFR的基础上加入临床参数的ROC曲线下面积为0.893(95%CI:0.835~0.952)。结论 CMR心肌灌注成像联合CT-FFR是阻塞性冠心病患者心血管不良事件发生的独立预测因素,在临床模型基础上加入CMR心肌灌注成像联合CT-FFR可显著提高对阻塞性冠心病患者心血管不良事件发生风险的预测效能。

准分子激光消蚀术在药物球囊扩张成形术治疗冠状动脉粥样硬化性心脏病中的应用

目的:探讨准分子激光消蚀术(ELCA)在药物球囊扩张成形术(DCB)治疗冠状动脉粥样硬化性心脏病(简称冠心病)中的应用价值。方法:选取2020年5月至2022年5月诊治的86例冠心病患者作为研究对象,采用随机数排秩法分为观察组(予以DCB联合ELCA治疗)与对照组(予以单纯DCB治疗),各43例。对比2组治疗前后肌酸激酶同工酶(CK-MB)、肌钙蛋白Ⅰ(cTnⅠ)、B型脑钠肽(BNP)、氨基末端脑钠肽前体(NT-proBNP)、小而密低密度脂蛋白(sd-LDL)、生长分化因子15(GDF-15)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)以及治疗后1 a内主要心血管不良事件(MACE)发生率。结果:治疗后观察组CK-MB、cTnⅠ、BNP、NT-proBNP、sd-LDL、GDF-15、LVESD、LVEDD降低的程度,LVEF升高的程度,均大于对照组(P<0.05)。观察组治疗后1 a内MACE发生率低于对照组(P=0.019)。结论:ELCA联合DCB治疗冠心病效果显著,有利于改善心功能和减轻心肌损伤,并降低MACE发生率。